Patent ID: 7728169

Claim:
A process of producing a pharmaceutical composition comprising formulating isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propyl-phenoxy]butyric acid or a pharmaceutically acceptable salt or hydrate thereof, with a pharmaceutically acceptable carrier or excipient, wherein the isolated orthorhombic crystalline form (i) is substantially free of monoclinic crystalline forms as evidenced by powder x-ray diffraction (PXRD) analysis showing the absence of doublet peaks between about 11.5 and 16 (2-Theta scale), and (ii) exhibits at least twice the solubility of a monoclinic crystalline form at 30° C. in aqueous ethanol.